Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion. That's the latest in a surge of M&A in the health care industry, combined deals of which have already reached $180 billion this year. Mylan (MYL) tumbled after Teva withdrew its $40 billion offer for the company in favor of the Allergan deal. Mylan's board had proved resistant to Teva's hostile takeover attempts. It was a new week but no fresh start for Wall Street as stocks extended losses into a fifth straight day, their longest losing streak in six months. Another selloff in Chinese equities pressured global markets. Keurig (GMCR) was higher despite a federal appeals court resurrecting a lawsuit which accused the coffee company of misleading its shareholders.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.